Manufacturing

Manufacturing

Apidel’s research facilities are capable of producing pilot batches of formulated drugs for in-vitro or animal studies. In order to ensure future quality manufacturing capability, the company has contracted with two FDA and EMEA inspected and approved synthesis companies, one in Europe and one in North America for the GMP synthesis of Apidel’s proprietary drug delivery polymer materials.

In addition, Apidel has identified and contracted with a pilot scale pharmaceutical manufacturing company in Europe, for the production of clinical testing batches of final products. In this way, Apidel can offer its partners timely access to GMP manufactured materials and testing batches.